Biotechnology News and Research RSS Feed - Biotechnology News and Research

Trends, R&D progress, and predicted revenues in RNAi therapies

Trends, R&D progress, and predicted revenues in RNAi therapies

When will RNAi therapies reach the market? Visiongain's brand new report shows you potential revenues to 2025, assessing data, trends, opportunities and prospects there. [More]
Lupin signs strategic asset purchase agreement with Temmler

Lupin signs strategic asset purchase agreement with Temmler

Pharma Major Lupin Limited today announced that it has entered into a strategic asset purchase agreement with TEMMLER PHARMA GMBH & CO. KG, a part of the Aenova Group, one of the world's largest pharmaceutical contract manufacturers, to acquire Temmler's specialty product portfolio subject to certain closing conditions. [More]
3SBio purchases entire equity interest in Zhejiang Wansheng

3SBio purchases entire equity interest in Zhejiang Wansheng

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced that it has acquired the entire equity interest in Zhejiang Wansheng Pharmaceutical Co., Ltd a limited liability company incorporated in the PRC for an aggregate consideration of RMB 528 million. [More]
Two UM researchers receive $500,000 to improve treatment for mild traumatic brain injury

Two UM researchers receive $500,000 to improve treatment for mild traumatic brain injury

Two University of Montana researchers were among six final winners nationally to receive $500,000 from the Head Health Challenge I, an up-to-$10 million program sponsored by General Electric Co. and the National Football League. [More]
Gladstone Institutes announces new business endeavor with Evotec and Dolby Family Ventures

Gladstone Institutes announces new business endeavor with Evotec and Dolby Family Ventures

The Gladstone Institutes announces the creation of Cure Network Ventures Inc. and Cure Network Dolby Acceleration Partners, LLC, a business endeavor with Dolby Family Ventures and Evotec AG, which will focus on Alzheimer's disease. Working through Cure Network Ventures, Inc., the new company will help expedite the translation of relevant scientific discoveries from the Gladstone Institute of Neurological Disease into the development of potential therapies. [More]
Amgen announces submission of supplemental New Drug Application to FDA for Kyprolis (carfilzomib)

Amgen announces submission of supplemental New Drug Application to FDA for Kyprolis (carfilzomib)

Amgen today announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration for Kyprolis (carfilzomib) for Injection to seek an expanded indication for the treatment of patients with a form of blood cancer, relapsed multiple myeloma, who have received at least one prior therapy. [More]
Lupin enters into definitive agreement to acquire GAVIS

Lupin enters into definitive agreement to acquire GAVIS

Pharma Major Lupin Limited has entered into a definitive agreement to acquire privately held GAVIS Pharmaceuticals LLC and Novel Laboratories Inc., subject to certain closing conditions, in a transaction valued at USD 880 million, cash free and debt free. [More]
Zinc coating of galvanized steel pipes can be long-term source of lead in water

Zinc coating of galvanized steel pipes can be long-term source of lead in water

When unsafe levels of lead are found in drinking water, the culprit has typically been lead pipes or lead-containing brass and bronze fittings, but in a new study researchers clearly show that lead present in the zinc coating of galvanized steel pipes can be a very significant long-term source of lead in water. [More]
Study shows regions of genome underlying IBD consistent around the world

Study shows regions of genome underlying IBD consistent around the world

The first genetic study of inflammatory bowel disease (IBD) to include individuals from diverse populations has shown that the regions of the genome underlying the disease are consistent around the world. This study, conducted under the auspices of the International IBD Genetics Consortium, included nearly 10,000 DNA samples from people of East Asian, Indian or Iranian descent and an existing set of 86,640 samples drawn from across Europe, North America and Oceania. [More]
KalVista raises $33 million in Series B financing to support development of plasma kallikrein inhibitors

KalVista raises $33 million in Series B financing to support development of plasma kallikrein inhibitors

KalVista Pharmaceuticals, a research-led pharmaceutical company, today announced it has raised $33 million in a Series B financing to support its research and clinical development programs. KalVista will use the funds to advance its proprietary portfolio of plasma kallikrein inhibitors for treating diabetic macular edema (DME) and hereditary angioedema (HAE). [More]
New TripAdvisor-style website launched to help researchers choose better tools for biomedical research

New TripAdvisor-style website launched to help researchers choose better tools for biomedical research

An international panel of leading scientists is launching a new TripAdvisor-style website aimed at helping researchers choose better-quality research tools - and avoiding potentially serious errors in biomedical research. [More]
New, nontoxic surgical glue helps heal wounds without scar or inflammation

New, nontoxic surgical glue helps heal wounds without scar or inflammation

One of the most basic yet important surgical skills to keep a patient alive and intact may be closing wounds. It seems that doctors will now get the job done with more ease thanks to new, nontoxic surgical glue that instantly seals a bleeding wound and helps it heal without a scar or inflammation. [More]
Synthetic sugar could be latest weapon against superbugs

Synthetic sugar could be latest weapon against superbugs

A special type of synthetic sugar could be the latest weapon in the fight against superbugs. A team of scientists from The University of Queensland and Queensland biotechnology company Alchemia have discovered a potential new class of antibiotics inspired by sugar molecules produced by bacteria. [More]
PAREXEL introduces next generation Perceptive MyTrials Analytics solution

PAREXEL introduces next generation Perceptive MyTrials Analytics solution

PAREXEL International Corporation, a leading global biopharmaceutical services provider, today launched the next generation of its Perceptive MyTrials platform with advanced analytics capabilities. With the Perceptive MyTrials Analytics solution, clinical trial sponsors can now use a mobile-enabled, single entry-point to access predictive data analytics for multiple studies simultaneously. [More]
New technique holds promise for improving glycoprotein-based pharmaceuticals

New technique holds promise for improving glycoprotein-based pharmaceuticals

Researchers from the University of Copenhagen have discovered a way of improving biotech drugs. Better, cheaper and more effective drugs to combat cancer, arthritis and many other disorders. [More]
Antibiotics may increase risk of juvenile arthritis

Antibiotics may increase risk of juvenile arthritis

Taking antibiotics may increase the risk that a child will develop juvenile arthritis, according to a study from Rutgers University, University of Pennsylvania and Nemours A.I. duPont Hospital for Children published today in Pediatrics. [More]
Natural supplement may improve quality of life for people who have celiac disease and gluten intolerance

Natural supplement may improve quality of life for people who have celiac disease and gluten intolerance

University of Alberta researchers may have found a way to help people with celiac disease enjoy the wide variety of foods they normally have to shun. [More]
New pilot study suggests new era of clinical research in Parkinson's disease

New pilot study suggests new era of clinical research in Parkinson's disease

A new pilot study in Parkinson's disease suggests a new era of clinical research which removes the barrier of distance for both scientists and volunteers. The research, which appears in the journal Digital Health, could also enable researchers to leverage the rapid growth in personal genetic testing to better diagnose, and potentially treat, a wide range of diseases. [More]
Protein delivery reagent assists neurodegeneration research

Protein delivery reagent assists neurodegeneration research

AMSBIO announces that Belgian researchers have cited use of BioPORTER Protein Delivery Reagent to introduce Tau seeds into HEK293 cells. BioPORTER Protein Delivery Reagent is a unique lipid formulation that allows direct translocation of proteins into living cells. [More]

Protagonist Therapeutics closes $40 million Series C financing

Protagonist Therapeutics, Inc., a company developing novel, orally stable peptide therapeutics for gastrointestinal diseases and disorders, today announced the closing of a $40 million Series C financing. [More]
Advertisement
Advertisement